Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-007 in persistent or recurrent cervical cancer
NCT00309959Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Nov 2006
- Primary completion
- Feb 2011
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in Cervical Cancer (CC), sponsored by GOG Foundation. Primary endpoints: Objective Tumor Response Rate at 5 years and Frequency and Severity of Observed Adverse Effects at 5 years. Started Nov 2006; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT00309959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309959.